Company / Accounts Receivable
Viatris Accounts Receivable History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$3.0B
FY2025
5-year range
$3.0B / $4.3B
FY2021-FY2025
Trend
-5.9%
vs FY2024
Sector context
#11 of 113
Health Care
What the data says
Among 113 Health Care companies, Viatris is in the top 10% for accounts receivable. Accounts Receivable has declined for 5 consecutive years, from $4.8B in FY2020 to $3.0B in FY2025.
Based on SEC 10-K filings.
$3.0B in FY2025 with a 5-year CAGR of -8.9%. Top quartile in the Health Care sector.
Declined from $3.7B to $3.0B over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -7.4%
- 5-Year CAGR
- -8.9%
- 10-Year CAGR
- -
Sector benchmark
Top 10% in Health CareTop 10% of 113This company $3.0B Sector average $1.1B
▼
+166.5% above sector average
Key checks
Key Insights
- Viatris's accounts receivable has declined for 5 consecutive years.
- 5-year CAGR of -8.9%, indicating a declining trend.
- In FY2025, accounts receivable decreased 5.9% year-over-year.
- Ranks #11 out of 113 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.0B | -5.9% |
| FY2024 | $3.2B | -12.9% |
| FY2023 | $3.7B | -3.0% |
| FY2022 | $3.8B | -10.6% |
| FY2021 | $4.3B | -11.9% |
| FY2020 | $4.8B | +58.4% |
| FY2019 | $3.1B | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026